Resolvin E1 metabolome in local inactivation during inflammation-resolution

Journal of Immunology

Volumn 180, Issue 5, 2008, Pages 3512-3519

  Hong, Song ^a,b   Porter, Timothy F ^a   Lu, Yan ^a,b   Oh, Sungwhan F ^a   Pillai, Padmini S ^a   Serhan, Charles N ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Louisiana State University Health Science Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10 DIHYDRO RVE1; 11 DIHYDRO RVE1; 18 OXO RVE1; 19 HYDROXY RVE1; 20 CARBOXY RVE1; 5,8,11,14,17 ICOSAPENTAENOIC ACID; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; NEW DRUG; RESOLVIN E1; UNCLASSIFIED DRUG; 5S,12R,18R TRIHYDROXY 6Z,8E,10E,14Z,16E EICOSAPENTAENOIC ACID; 5S,12R,18R-TRIHYDROXY-6Z,8E,10E,14Z,16E-EICOSAPENTAENOIC ACID; AUTACOID; DRUG DERIVATIVE; ICOSAPENTAENOIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD; CELL SPECIFICITY; CELL TYPE; COMPARATIVE STUDY; CONJUGATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CONCENTRATION; DRUG HYDROXYLATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SPECIFICITY; EXUDATE; HOMEOSTASIS; HUMAN; HUMAN CELL; HYDROXYLATION; IN VIVO STUDY; KIDNEY; LIPIDOMICS; LIVER; MACROPHAGE; MALE; METABOLIC ACTIVATION; METABOLOME; MOUSE; NEUTROPHIL; NONHUMAN; PERITONITIS; PHAGOCYTOSIS; PRIORITY JOURNAL; REDUCTION; SPLEEN; ANIMAL; ASCITES FLUID; DRUG ANTAGONISM; IMMUNOLOGY; INFLAMMATION; METABOLISM; MOUSE STRAIN; PATHOLOGY; PERITONEUM MACROPHAGE; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASCITIC FLUID; EICOSAPENTAENOIC ACID; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED STRAINS; NEUTROPHILS; PHAGOCYTOSIS; SIGNAL TRANSDUCTION;

EID: 49149116971     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.5.3512     Document Type: Article

References (39)

1. Serhan, C. N. 2007. Resolution phases of inflammation: novel endogenous antiinflammatory and pro-resolving lipid mediators and pathways. Annu. Rev. Immunol. 25: 101-137.
2. Serhan, C. N., and J. Savill. 2005. Resolution of inflammation: the beginning programs the end. Nat. Immunol. 6: 1191-1197.
3. Gilroy, D. W., T. Lawrence, M. Perretti, and A. G. Rossi. 2004. Inflammatory resolution: new opportunities for drug discovery. Nat. Rev. Drug Discov. 3: 401-416.
4. Bannenberg, G. L., N. Chiang, A. Ariel, M. Arita, E. Tjonahen, K. H. Gotlinger, S. Hong, and C. N. Serhan. 2005. Molecular circuits of resolution: formation and actions of resolvins and protectins. J. Immunol. 174: 4345-4355.
5. Serhan, C. N., C. B. Clish, J. Brannon, S. P. Colgan, N. Chiang, and K. Gronert. 2000. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. 192: 1197-1204.
6. Hudert, C. A., K. H. Weylandt, J. Wang, Y. Lu, S. Hong, A. Dignass, C. N. Serhan, and J. X. Kang. 2006. Transgenic mice rich in endogenous n-3 fatty acids are protected from colitis. Proc. Natl. Acad. Sci. USA 103: 11276-11281.
7. Arita, M., M. Yoshida, S. Hong, E. Tjonahen, J. N. Glickman, N. A. Petasis, R. S. Blumberg, and C. N. Serhan. 2005. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc. Natl. Acad. Sci. USA 102: 7671-7676.
8. Connor, K. M., J. P. SanGiovanni, C. Lofqvist, C. M. Aderman, J. Chen, A. Higuchi, S. Hong, E. A. Pravda, S. Majchrzak, D. Carper, et al. 2007. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat. Med. 13: 868-873.
9. Hasturk, H., A. Kantarci, T. Ohira, M. Arita, N. Ebrahimi, N. Chiang, N. A. Petasis, B. D. Levy, C. N. Serhan, and T. E. Van Dyke. 2006. RvE1 protects from local inflammation and osteoclast mediated bone destruction in periodontitis. FASEB J. 20: 401-403.
10. Schwab, J. M., N. Chiang, M. Arita, and C. N. Serhan. 2007. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447: 869-874.
11. Clish, C. B., B. D. Levy, N. Chiang, H.-H. Tai, and C. N. Serhan. 2000. Oxidoreductases in lipoxin A4 metabolic inactivation. J. Biol. Chem. 275: 25372-25380.
12. Arita, M., S. Oh, T. Chonan, S. Hong, S. Elangovan, Y.-P. Sun, J. Uddin, N. A. Petasis, and C. N. Serhan. 2006. Metabolic inactivation of resolvin E1 and stabilization of its anti-inflammatory actions. J. Biol. Chem. 281: 22847-22854.
13. Arita, M., F. Bianchini, J. Aliberti, A. Sher, N. Chiang, S. Hong, R. Yang, N. A. Petasis, and C. N. Serhan. 2005. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J. Exp. Med. 201: 713-722.
14. Calder, P. C. 2006. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am. J. Clin. Nutr. 83: 1505S-1519S.
15. Salem, N., Jr., B. Litman, H.-Y. Kim, and K. Gawrisch. 2001. Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 36: 945-959.
16. Freeman, M. P. 2000. Omega-3 fatty acids in psychiatry: a review. Ann. Clin. Psychiatry 12: 159-165.
17. Holub, D. J., and B. J. Holub. 2004. Omega-3 fatty acids from fish oils and cardiovascular disease. Mol. Cell. Biochem. 263: 217-225.
18. Weylandt, K. H., J. X. Kang, B. Wiedenmann, and D. C. Baumgart. 2007. Lipoxins and resolvins in inflammatory bowel disease. Inflamm. Bowel Dis. 13: 797-799.
19. Serhan, C. N., S. Hong, K. Gronert, S. P. Colgan, P. R. Devchand, G. Mirick, and R.-L. Moussignac. 2002. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196: 1025-1037.
20. Hong, S., K. Gronert, P. Devchand, R.-L. Moussignac, and C. N. Serhan. 2003. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood and glial cells: autacoids in anti-inflammation. J. Biol. Chem. 278: 14677-14687.
21. Lu, Y., S. Hong, R. Yang, J. Uddin, K. H. Gotlinger, N. A. Petasis, and C. N. Serhan. 2007. Identification of endogenous resolvin E1 and other lipid mediators derived from eicosapentaenoic acid via electrospray low energy tandem mass spectrometry: spectra and fragmentation mechanisms. Rapid Commun. Mass Spectrom. 21: 7-22.
22. Godson, C., S. Mitchell, K. Harvey, N. A. Petasis, N. Hogg, and H. R. Brady. 2000. Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J. Immunol. 164: 1663-1667.
23. Laethem, R. M., M. Balazy, J. R. Falck, C. L. Laethem, and D. R. Koop. 1993. Formation of 19(S)-, 19(R)-, and 18(R)-hydroxyeicosatetraenoic acids by alcohol-inducible cytochrome P450 2E1. J. Biol. Chem. 268: 12912-12918.
24. Bylund, J., M. Hidestrand, M. Ingelman-Sundberg, and E. H. Oliw. 2000. Identification of CYP4F8 in human seminal vesicles as a prominent 19-hydroxylase of prostaglandin endoperoxides. J. Biol. Chem. 275: 21844-21849.
25. Yokomizo, T., T. Izumi, T. Takahashi, T. Kasama, Y. Kobayashi, F. Sato, Y. Taketani, and T. Shimizu. 1993. Enzymatic inactivation of leukotriene B4 by a novel enzyme found in the porcine kidney: purification and properties of leukotriene B4 12-hydroxydehydrogenase. J. Biol. Chem. 268: 18128-18135.
26. Tai, H. H., C. M. Ensor, M. Tong, H. Zhou, and F. Yan. 2002. Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat. 68-69: 483-493.
27. 4 metabolism by differentiated HL-60 cells and human monocytes: conversion to novel 15-oxo and dihydro products. Biochemistry 32: 6313-6319.
28. Mitchell, S., G. Thomas, K. Harvey, D. Cottell, K. Reville, G. Berlasconi, N. A. Petasis, L. Erwig, A. J. Rees, J. Savill, et al. 2002. Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J. Am. Soc. Nephrol. 13: 2497-2507.
29. 4 analog attenuates lipopolysaccharide-induced acute lung injury in mice: the role of heme oxygenase-1. Anesth. Analg. 104: 369-377.
30. 4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proc. Natl. Acad. Sci. USA 101: 15736-15741.
31. Serhan, C. N. 2005. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukotrienes Essent. Fatty Acids 73: 141-162.
32. Kowal-Bielecka, O., K. Kowal, O. Distler, and S. Gay. 2007. Mechanisms of disease: leukotrienes andlipoxins in scleroderma lung disease: insights and potential therapeutic implications. Nat. Clin. Pract. Rheumatol. 3: 43-51.
33. Harris, W. S., K. J. Reid, S. A. Sands, and J. A. Spertus. 2007. Blood omega-3 and trans fatty acids in middle-aged acute coronary syndrome patients. Am. J. Cardiol. 99: 154-158.
34. Yokoyama, M., H. Origasa, M. Matsuzaki, Y. Matsuzawa, Y. Saito, Y. Ishikawa, S. Oikawa, J. Sasaki, H. Hishida, H. Itakura, et al. 2007. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369: 1090-1098.
35. Serhan, C. N., S. D. Brain, C. D. Buckley, D. W. Gilroy, C. Haslett, L. A. J. O'Neill, M. Perretti, A. G. Rossi, and J. L. Wallace. 2007. Resolution of inflammation: state of the art, definitions and terms. FASEB J. 21: 325-332.
36. Hong, S., W. C. Gordon, Y. Lu, V. L. Marcheselli, and N. G. Bazan. 2007. Lipidomic approach to define pro- and anti-inflammatory mediators in laser-induce choroidal neovascularization. Invest. Ophthalmol. Visual Sci. 48: e-abstract 6014.
37. Birnbaum, Y., Y. Ye, Y. Lin, S. Y. Freeberg, M.-H. Huang, J. R. Perez-Polo, and B. F. Uretsky. 2007. Aspirin augments 15-epi-lipoxin A4 production by lipopolysaccharide, but blocks the pioglitazone and atorvastatin induction of 15-epi-lipoxin A4 in the rat heart. Prostaglandins Other Lipid Mediat. 83: 89-98.
38. Birnbaum, Y., Y. Ye, Y. Lin, S. Y. Freeberg, S. P. Nishi, J. D. Martinez, M.-H. Huang, B. F. Uretsky, and J. R. Perez-Polo. 2006. Augmentation of myocardial production of 15-epi-lipoxin-A4 by pioglitazone and atorvastatin in the rat. Circulation 114: 929-935.
39. Birnbaum, Y., Y. Ye, S. Rosanio, S. Tavackoli, Z. Y. Hu, E. R. Schwarz, and B. F. Uretsky. 2005. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. Cardiovasc. Res. 65: 345-355.